NCT00130832View on ClinicalTrials.gov

Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

735

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Rotavirus InfectionsGastroenteritis
Interventions
BIOLOGICAL

Rotavirus Vaccine, Live, Oral, Pentavalent

Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.

BIOLOGICAL

Comparator: Oral Poliovirus Vaccine (OPV)

Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.

BIOLOGICAL

Comparator: Oral Poliovirus Vaccine (OPV) (staggered)

Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00130832 - Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED) | Biotech Hunter | Biotech Hunter